Advanced Enzyme Technologies Ltd vs Akums Drugs Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 15, 2026

Key Highlights

The Latest Trading Price of Advanced Enzyme Technologies Ltd is ₹ 369.85 as of 12 Jun 15:30 . The P/E Ratio of Advanced Enzyme Technologies Ltd changed from 26.4 on March 2021 to 23.8 on March 2025 . This represents a CAGR of -2.05% over 5 yearsThe P/E Ratio of Akums Drugs & Pharmaceuticals Ltd changed from 21.5 on March 2025 to 21.5 on March 2025 . This represents a CAGR of 0.00% over 1 years The Market Cap of Advanced Enzyme Technologies Ltd changed from ₹ 3852 crore on March 2021 to ₹ 3120 crore on March 2025 . This represents a CAGR of -4.13% over 5 yearsThe Market Cap of Akums Drugs & Pharmaceuticals Ltd changed from ₹ 7469 crore on March 2025 to ₹ 7469 crore on March 2025 . This represents a CAGR of 0.00% over 1 years The revenue of Advanced Enzyme Technologies Ltd for the Mar '26 is ₹ 210.71 crore as compare to the Dec '25 revenue of ₹ 191.66 crore. This represent the growth of 9.94% The revenue of Akums Drugs & Pharmaceuticals Ltd for the Mar '26 is ₹ 1193 crore as compare to the Dec '25 revenue of ₹ 1193 crore. This represent the decline of -0.06% The ebitda of Advanced Enzyme Technologies Ltd for the Mar '26 is ₹ 70.57 crore as compare to the Dec '25 ebitda of ₹ 69.07 crore. This represent the growth of 2.17% The ebitda of Akums Drugs & Pharmaceuticals Ltd for the Mar '26 is ₹ 185.23 crore as compare to the Dec '25 ebitda of ₹ 162.96 crore. This represent the growth of 13.67% The net profit of Advanced Enzyme Technologies Ltd changed from ₹ 34.98 crore to ₹ 45.25 crore over 8 quarters. This represents a CAGR of 13.74% The net profit of Akums Drugs & Pharmaceuticals Ltd changed from ₹ 61.21 crore to ₹ 81.34 crore over 8 quarters. This represents a CAGR of 15.28% The Dividend Payout of Advanced Enzyme Technologies Ltd changed from 14.16 % on March 2021 to 56.81 % on March 2025 . This represents a CAGR of 32.03% over 5 yearsThe Dividend Payout of Akums Drugs & Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Advanced Enzyme Technologies Ltd

Advanced Enzyme Technologies Limited (AETL) is largest Indian enzyme company that transformed business globally in the manufacturing and sale of enzymes.
The Company was incorporated, as a Private Company on March 15, 1989 as 'Advanced Biochemicals Private Limited' in Maharashtra.
It thereafter converted the status into a Public Company and the name of the Company was changed to Advanced Biochemicals Limited on May 28, 1992 and further was changed to Advanced Enzyme Technologies Limited via fresh Certificate of Incorporation at RoC, Mumbai on August 19, 2005. In 2011, the company took over Cal-India Foods International, giving the company direct presence in USA. In 2012, the company took over Advanced Supplementary Technologies Corporation for consolidating its presence in USA. Advanced Enzyme Technologies Limited came out with its Initial Public Offer (IPO) of 4,594,875 Equity shares of Rs 10 each at an issue price of Rs 896 per Equity share ( Rs 810 per Equity share for eligible employees), consisting of fresh issue of 560,405 Equity shares and an Offer for Sale of 4,034,470 Equity shares by Selling Shareholders.

About Akums Drugs & Pharmaceuticals Ltd

Akums Drugs and Pharmaceuticals Limited was incorporated vide Certificate of Incorporation dated April 19, 2004 and received a Certificate for Commencement of Business dated May 13, 2004 issued by the RoC. Alkums Drugs & Pharmas are a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas.
They are into sale of branded pharmaceutical formulations and manufacturing of Active Pharmaceutical Ingredients.
Some of the other services include formulation research and development, preparation and filing of regulatory dossiers into the Indian and global markets, and other testing services.
Some of manufacturing units have been accredited by various global regulatory agencies such as the European Good Manufacturing Practice, the World Health Organization Good Manufacturing Practice and the United States National Sanitation Foundation.

FAQs for the comparison of Advanced Enzyme Technologies Ltd and Akums Drugs & Pharmaceuticals Ltd

Which company has a larger market capitalization, Advanced Enzyme Technologies Ltd or Akums Drugs & Pharmaceuticals Ltd?

Market cap of Advanced Enzyme Technologies Ltd is 4,141 Cr while Market cap of Akums Drugs & Pharmaceuticals Ltd is 9,804 Cr

What are the key factors driving the stock performance of Advanced Enzyme Technologies Ltd and Akums Drugs & Pharmaceuticals Ltd?

The stock performance of Advanced Enzyme Technologies Ltd and Akums Drugs & Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Advanced Enzyme Technologies Ltd and Akums Drugs & Pharmaceuticals Ltd?

As of June 15, 2026, the Advanced Enzyme Technologies Ltd stock price is INR ₹369.85. On the other hand, Akums Drugs & Pharmaceuticals Ltd stock price is INR ₹622.95.

How do dividend payouts of Advanced Enzyme Technologies Ltd and Akums Drugs & Pharmaceuticals Ltd compare?

To compare the dividend payouts of Advanced Enzyme Technologies Ltd and Akums Drugs & Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.